AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: small molecule

newssourceFORcompanyinformationcontent1releasesmarket

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

Varda Space Industries Launches W-4 with the FAA’s First-Ever Reentry Vehicle Operator License and Debuts an In-House Satellite Bus

The company's fourth mission will focus on demonstrating its new satellite bus, an in-house heatshield, and solution-based pharmaceutical processing. EL SEGUNDO, Calif., June 23,...

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation of...

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSmall molecule

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers